Clinical Trial

CVL006 Combination Therapy in Advanced Solid Tumors

Study acronym: CVL006-T1002
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with pemetrexed + carboplatin/SKB264/ DS-8201a/ Enfortumab Vedotin in patients with advanced solid tumors.
Trial Details
NCT Number NCT07157956
Lead Sponsor Convalife (Shanghai) Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 318 participants
Start Date 2025-09-10
Primary Completion 2028-08-12 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-05